Skip to content
    Reviews

    Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence

    Guan et alFrontiers in Oncology

    Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence
    A systematic review and meta-analysis evaluated the efficacy of oral selective estrogen receptor degraders (SERDs) across both early-stage and advanced estrogen receptor-positive (ER+), HER2-negative breast cancer. The synthesis incorporated ten randomized controlled trials (one adjuvant study, n = 4,170; nine metastatic studies) investigating agents including giredestrant, imlunestrant, elacestrant, camizestrant, vepdegestrant, and amcenestrant versus standard endocrine therapy.
    In early-stage disease, evidence from the adjuvant Phase III lidERA trial revealed that giredestrant significantly reduced the risk of recurrence or death, improving invasive disease-free survival compared with standard endocrine therapy (HR 0.70; 95% CI 0.57–0.87; P = 0.0014). This represents the first positive adjuvant Phase III trial result for an oral SERD, supporting its potential role in early-stage management.
    In the metastatic setting, random-effects pooled analysis of six monotherapy trials encompassing 2,502 patients demonstrated a statistically significant progression-free survival (PFS) advantage for oral degraders over standard endocrine therapy (HR 0.815; 95% CI 0.718–0.924; P = 0.0014; I² = 35.2%). The PFS benefit was particularly pronounced among patients harboring ESR1 mutations, achieving an HR of 0.617 (95% CI 0.527–0.723; P < 0.0001) with zero heterogeneity across five independent trials (I² = 0%).
    These metastatic findings remained robust across multiple prespecified sensitivity analyses, including restricting the cohort to Phase III trials (HR 0.811; I² = 5.8%), excluding the PROTAC agent (HR 0.807), leave-one-out iterations (HR range 0.790–0.843), and Bayesian re-analysis (posterior median HR 0.814; 95% credible interval 0.678–0.969). Funnel plot assessment via Egger's test showed no statistically significant publication asymmetry (P = 0.40), although statistical power was limited by the small number of trials (k = 6).

    Key Takeaways

    • In the adjuvant setting, the Phase III lidERA trial (n = 4,170) demonstrated that giredestrant significantly improved invasive disease-free survival compared with standard endocrine therapy (HR 0.70; 95% CI 0.57–0.87; P = 0.0014).
    • In metastatic ER-positive, HER2-negative disease, pooled analysis of six oral degrader monotherapy trials (n = 2,502) showed a significant progression-free survival benefit over standard endocrine therapy (HR 0.815; 95% CI 0.718–0.924; P = 0.0014), with the greatest efficacy observed in tumors harboring ESR1 mutations (HR 0.617; 95% CI 0.527–0.723; P < 0.0001; I² = 0%).
    Read the original sourceFrontiers in Oncology